DTC
BCAX

Deep Track Capital’s Bicara Therapeutics BCAX Stock Holding History

Deep Track Capital’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$122M Buy
4,100,000
+37,500
+0.9% +$837K 1.77% 25
2026
Q1 		$80.8M Buy
4,062,500
+1,448,496
+55% +$24.9M 1.32% 25
2025
Q4 		$44M Buy
2,614,004
+187,347
+8% +$3.2M 0.78% 33
2025
Q3 		$38.3M Hold
2,426,657
– – 1.07% 30
2025
Q2 		$22.5M Buy
2,426,657
+426,657
+21% +$5.08M 0.72% 36
2025
Q1 		$26.1M Hold
2,000,000
– – 0.84% 31
2024
Q4 		$34.8M Buy
2,000,000
+1,203,148
+151% +$25M 1.3% 26
2024
Q3 		$20.3M Buy
+796,852
New +$20.3M 0.64% 43

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deep Track Capital's BCAX Position: Q2 2026 in Review

Deep Track Capital increased its Bicara Therapeutics (BCAX) stake by 0.92% in Q2 2026, buying an estimated $837K and bringing the position to 4,100,000 shares worth $122M. The position accounts for 1.77% of the portfolio, ranked #25.

Deep Track Capital first reported a position in BCAX in Q3 2024 and has held it in 8 quarters since. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Deep Track Capital held 4,100,000 shares of Bicara Therapeutics worth $122M as of Q2 2026.
  • Deep Track Capital bought 37,500 Bicara Therapeutics shares in Q2 2026, an estimated $837K.
  • Bicara Therapeutics made up 1.77% of Deep Track Capital's portfolio in Q2 2026, its #25 holding.
  • Deep Track Capital first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Deep Track Capital's 13F filing for Q2 2026, filed 14 Aug 2026.